AN3365

AN3365 is our lead investigational antibiotic product development candidate for the potential treatment of infections caused by Gram-negative bacteria.

About Gram-Negative Infections

Gram-negative infections are a type of bacterial infection caused by a broad class of bacteria called Gram-negative bacteria and are most commonly acquired and treated in the hospital setting.

Current Gram-Negative Therapies

Traditionally, Gram-negative infections have been treated with antibiotics, particularly beta-lactams, including penicillins, cephalosporins and carbapenems, and quinolones, including flouroquinolones. However, the effectiveness of existing antibiotics has been declining due to increasingly prevalent drug resistance and there is an ongoing need for novel antibiotics.

Our Product Candidate: AN3365

AN3365 is our wholly-owned investigational antibiotic product development candidate for the potential treatment of infections caused by Gram-negative bacteria, including E. coli, Klebsiella pneumoniae, Citrobacter spp., S. marcescens, P. vulgaris, Providentia spp., Pseudomonas aeruginosa and Enterobacter spp.

We are currently considering our options for further development, if any, of this compound.